[	0	1	O
Retinochoroidopathy	1	20	O
after	21	26	O
intravitreal	27	39	O
anti	40	44	O
-	44	45	O
VEGF	45	49	B-Gene_or_gene_product
treatment	50	59	O
]	59	60	O

A	62	63	O
74	64	66	O
-	66	67	O
year	67	71	O
-	71	72	O
old	72	75	O
man	76	79	B-Organism
presented	80	89	O
with	90	94	O
persistent	95	105	O
metamorphopsias	106	121	O
of	122	124	O
the	125	128	O
right	129	134	O
eye	135	138	B-Organ
2	139	140	O
weeks	141	146	O
after	147	152	O
intravitreal	153	165	O
injection	166	175	O
of	176	178	O
bevacizumab	179	190	B-Drug_or_compound
to	191	193	O
treat	194	199	O
choroidal	200	209	O
neovascularization	210	228	O
due	229	232	O
to	233	235	O
exudative	236	245	O
age	246	249	O
-	249	250	O
related	250	257	O
macular	258	265	B-Tissue
degeneration	266	278	O
.	278	279	O

The	280	283	O
diagnosis	284	293	O
reached	294	301	O
was	302	305	O
retinochoroiditis	306	323	O
as	324	326	O
an	327	329	O
occult	330	336	O
manifestation	337	350	O
of	351	353	O
sarcoidosis	354	365	O
,	365	366	O
possibly	367	375	O
resulting	376	385	O
from	386	390	O
an	391	393	O
intravitreal	394	406	O
injection	407	416	O
of	417	419	O
bevacizumab	420	431	B-Drug_or_compound
.	431	432	O

The	433	436	O
patient	437	444	B-Organism
received	445	453	O
a	454	455	O
prescription	456	468	O
for	469	472	O
100	473	476	O
mg	477	479	O
Ultralan	480	488	B-Drug_or_compound
to	489	491	O
be	492	494	O
taken	495	500	O
daily	501	506	O
for	507	510	O
3	511	512	O
days	513	517	O
and	518	521	O
then	522	526	O
tapered	527	534	O
in	535	537	O
3	538	539	O
day	540	543	O
steps	544	549	O
.	549	550	O

During	551	557	O
the	558	561	O
further	562	569	O
course	570	576	O
no	577	579	O
deterioration	580	593	O
of	594	596	O
the	597	600	O
condition	601	610	O
was	611	614	O
observed	615	623	O
.	623	624	O

